Thorsten Rieckmann
Dr. phil. nat.
Thorsten Rieckmann
  • 1.Arbeitsbereich
Deutsch (Muttersprache)



  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

The inflammation-reducing compatible solute ectoine does not impair the cytotoxic effect of ionizing radiation on head and neck cancer cells
Rieckmann T, Gatzemeier F, Christiansen S, Rothkamm K, Münscher A
SCI REP-UK. 2019;9(1):6594.

The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective
Rieckmann T, Kriegs M
Clinical and translational radiation oncology. 2019;17:47-50.

Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy.
Rödel F, Martin D, Balermpas P, Wieland U, Winkelmann R, Rieckmann T, Falk S, Rödel C, Fokas E
BBA-REV CANCER. 2019;1871(1):126-137.

Current studies of immunotherapy in head and neck cancer
Dogan V, Rieckmann T, Münscher A, Busch C
CLIN OTOLARYNGOL. 2018;43(1):13-21.

G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1
Busch C, Kröger M, Jensen J, Kriegs M, Gatzemeier F, Petersen C, Münscher A, Rothkamm K, Rieckmann T
RADIOTHER ONCOL. 2017;122(2):260-266.

Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines
Ziemann F, Seltzsam S, Dreffke K, Preising S, Arenz A, Subtil F, Rieckmann T, Engenhart-Cabillic R, Dikomey E, Wittig A
ONCOTARGET. 2017;8(62):105170-105183.

DNA Repair
Borgmann K, Köcher S, Kriegs M, Mansour Khalfallah W, Parplys A, Rieckmann T, Rothkamm K
2016. Molecular Radio-Oncology. Baumann M, Krause M, Cordes N (Hrsg.). 1. Aufl. Berlin Heidelberg: Springer, 1-24.

Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines
Busch C, Becker B, Kriegs M, Gatzemeier F, Krüger K, Möckelmann N, Fritz G, Petersen C, Knecht R, Rothkamm K, Rieckmann T
ONCOTARGET. 2016;7(24):35832-35842.

Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer
Bussmann L, Busch C, Lörincz B, Rieckmann T, Block A, Knecht R
EUR ARCH OTO-RHINO-L. 2016;273(12):4073-4080.

Radiation DNA damage and use in cancer/therapeutics-translation of radiation modifiers
Dikomey E, Borgmann K, Köcher S, Kriegs M, Mansour Khalfallah W, Parplys A, Rieckmann T, Rothkamm K
2016. DNA Repair in Cancer Therapy. Kelley M, Fishel M (Hrsg.). 2. Aufl. London: Elsevier Science, 329 - 352.

DNA repair after oncological therapy (radiotherapy and chemotherapy)
Dikomey E, Borgmann K, Kriegs M, Mansour Khalfallah W, Petersen C, Rieckmann T
2016. Oxford Textbook of Oncology. Kerr D, Haller D, van de Velde C, Baumann M (Hrsg.). 3. Aufl. Oxford: Oxford University Press, 82-85.

Targeted nanoparticles for tumour radiotherapy enhancement - the long dawn of a golden era?
Gargioni E, Schulz F, Raabe A, Burdak-Rothkamm S, Rieckmann T, Rothkamm K
Ann Transl Med. 2016;4(24):523.

Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests
Kriegs M, Kasten-Pisula U, Riepen B, Hoffer K, Struve N, Myllynen L, Braig F, Binder M, Rieckmann T, Grénman R, Petersen C, Dikomey E, Rothkamm K
ONCOTARGET. 2016;7(29):45122-45133.

Situation of young radiation oncologists, medical physicists and radiation biologists in German-speaking countries: Results from a web-based survey of the Young DEGRO working group
Krug D, Baumann R, Rieckmann T, Fokas E, Gauer T, Niyazi M
STRAHLENTHER ONKOL. 2016;192(8):507-15.

Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells
Möckelmann N, Rieckmann T, Busch C, Becker B, Gleißner L, Hoffer K, Omniczynski M, Steinmeister L, Laban S, Grénman R, Petersen C, Rothkamm K, Dikomey E, Knecht R, Kriegs M
ONCOTARGET. 2016;7(17):23542-51.

HPV and Radiation Sensitivity
De Costa A, Rieckmann T, Kimple R
2015. Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer. Miller D, Stack M (Hrsg.). 1. Aufl. Springer, 243-289.

Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest
Kriegs M, Gurtner K, Can Y, Brammer I, Rieckmann T, Oertel R, Wysocki M, Dorniok F, Gal A, Grob T, Laban S, Kasten-Pisula U, Petersen C, Baumann M, Krause M, Dikomey E
RADIOTHER ONCOL. 2015;115(1):120-7.

EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells
Struve N, Riedel M, Schulte A, Rieckmann T, Grob T, Gal A, Rothkamm K, Lamszus K, Petersen C, Dikomey E, Kriegs M
ONCOTARGET. 2015;6(32):33867-77.

The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines
Güster J, Weissleder S, Busch C, Kriegs M, Petersen C, Knecht R, Dikomey E, Rieckmann T
RADIOTHER ONCOL. 2014;113(3):345-51.

HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1
Busch C, Kriegs M, Laban S, Tribius S, Knecht R, Petersen C, Dikomey E, Rieckmann T
RADIOTHER ONCOL. 2013;108(3):495-9.

Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma.
Mansour Khalfallah W, Bogdanova N, Kasten-Pisula U, Rieckmann T, Köcher S, Borgmann K, Baumann M, Krause M, Petersen C, Hu H, Gatti R, Dikomey E, Dörk T, Dahm-Daphi J
RADIOTHER ONCOL. 2013;106(1):147-154.

p53 modulates homologous recombination at I-SceI-induced double-strand breaks through cell-cycle regulation.
Rieckmann T, Kriegs M, Nitsch L, Hoffer K, Rohaly G, Köcher S, Petersen C, Dikomey E, Dornreiter I, Dahm-Daphi J
ONCOGENE. 2013;32(8):968-975.

HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity.
Rieckmann T, Tribius S, Grob T, Meyer F, Busch C, Petersen C, Dikomey E, Kriegs M
RADIOTHER ONCOL. 2013;107(2):242-246.

Radiation-induced double-strand breaks require ATM but not Artemis for homologous recombination during S-phase.
Köcher S, Rieckmann T, Rohaly G, Mansour W, Dikomey E, Dornreiter I, Dahm-Daphi J
NUCLEIC ACIDS RES. 2012;40(17):8336-8347.

In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status.
Myllynen L, Rieckmann T, Dahm-Daphi J, Kasten-Pisula U, Petersen C, Dikomey E, Kriegs M
RADIOTHER ONCOL. 2011;101(1):147-151.

Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know.
Tribius S, Ihloff A, Rieckmann T, Petersen C, Hoffmann M
CANCER LETT. 2011;304(2):71-79.

The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining.
Kriegs M, Kasten-Pisula U, Rieckmann T, Holst K, Saker J, Dahm-Daphi J, Dikomey E
DNA REPAIR. 2010;9(8):889-897.

Rapid fusion and syncytium formation of heterologous cells upon expression of the FGFRL1 receptor.
Steinberg F, Gerber S, Rieckmann T, Trueb B
J BIOL CHEM. 2010;285(48):37704-37715.

Letzte Aktualisierung aus dem FIS: 15.10.2019 - 00:37 Uhr